TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
▌TickerSpark Feed

pipeline

Everything tagged "pipeline" across the TickerSpark archives.

Krystal Biotech's Q2 beat was not enough to save the stock
OpinionKRYS

Krystal Biotech's Q2 beat was not enough to save the stock

KRYS's 8.4% post-earnings drop says the market is pricing single-product risk harder than near-term growth. Vyjuvek is scaling, but a 21.23x sales multiple leaves little room for pipeline delays or reimbursement friction.

Aug 4, 2026·3 MIN
BiotechnologyValuationPipeline
Arrowhead Pharmaceuticals (ARWR): REDEMPLO Launch Meets RNAi Upside
Research ReportARWR

Arrowhead Pharmaceuticals (ARWR): REDEMPLO Launch Meets RNAi Upside

Arrowhead is transitioning from platform biotech to commercial-stage RNAi company, with REDEMPLO launch traction, a fortified balance sheet, and a deep partnered pipeline. The stock still depends on execution, but the setup is constructive for medium-term investors.

Jul 22, 2026·28 MIN
HealthcareBiotechnologyBiotechnology
Moderna’s rally is the first real post-COVID bull case the market can underwrite
OpinionMRNA

Moderna’s rally is the first real post-COVID bull case the market can underwrite

Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.

Jun 27, 2026·4 MIN
BiotechFDAPipeline
← Previous
Page 2 of 2
▌On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌Today's Top MoverGPN
▲9.95%
Global Payments Inc. · $91.83

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA